ILUVATAR COREX (09903) bank credit lines reach RMB12 billion; diversified financing system strengthens supply chain and delivery assurance.
ILUVATAR COREX (09903)'s latest announcement shows that the company has obtained a total of RMB12 billion in bank credit lines, of which more than 80% remains unused.
ILUVATAR COREX (09903) announced in its latest filing that the company has obtained a total of RMB12 billion in bank credit lines, of which more than 80% remains undrawn. Meanwhile, the company completed approximately HK$7 billion in placement financing in July this year, forming a diversified funding assurance system that combines bank credit with equity financing.
The company stated that sufficient financing support can provide strong backing for business expansion, upstream resource procurement, and advance inventory stocking, while also reserving greater room for capital allocation to cope with supply chain fluctuations in the industry. Analysis suggests that driven by growing AI computing power demand, key material supply and large-scale delivery capability are becoming important components of GPU companies' competitiveness, and financial strength and financing capability are increasingly drawing market attention.
The ample bank credit lines, combined with the previous placement financing, are expected to enhance ILUVATAR COREX's supply chain resource assurance capability and efficiency in responding to customer demand, provide support for subsequent product delivery and business growth, and create favorable conditions for the company to seize opportunities in the development of the domestic computing power industry.
Related Articles

JPMorgan Maintains "Neutral" Rating on BioNTech (BNTX.US): Bullish on the Potential of pumitamig Combined with B7-H3 ADC, but Key Data Readout Not Expected Until After 2028

HK Stock Market Move | DUIBA (01753) rose over 7% in late trading as its AI short drama business scales rapidly; management expects three consecutive months of net profit.

HK Stock Market Move | "China's No. 1 Direct Drive Stock" DIRECT DRIVE (06731) Surges Over 10% to a New High, Three-Year Compound Growth Rate Reaches 300.8%
JPMorgan Maintains "Neutral" Rating on BioNTech (BNTX.US): Bullish on the Potential of pumitamig Combined with B7-H3 ADC, but Key Data Readout Not Expected Until After 2028

HK Stock Market Move | DUIBA (01753) rose over 7% in late trading as its AI short drama business scales rapidly; management expects three consecutive months of net profit.

HK Stock Market Move | "China's No. 1 Direct Drive Stock" DIRECT DRIVE (06731) Surges Over 10% to a New High, Three-Year Compound Growth Rate Reaches 300.8%






